attention on the micro RNA miR-16, a known tumor suppressor that has been reported to 1 4 0 regulate CDC25A in response to , and which was found to be 1 4 1 down-regulated in murine FDCP-1 cells that express FLT3-ITD (17). First, we tested the 1 4 2 impact of FLT3 inhibition on miR-16 level in human MOLM-14 and MV4-11 cells. As 1 4 3 shown in figure 3A , miR-16 was significantly increased after two hours of FLT3-ITD 1 4 4 inhibition. In order to investigate the physiological meaning of these data, we established the 1 4 5 status of miR-16 expression in primary cells from AML patients. As shown in figure 3B , 1 4 6 miR-16 level was significantly lower in AML cells that express FLT3-ITD, further 1 4 7
confirming that FLT3-ITD activity negatively regulates miR-16 expression. We then 1 4 8
examined whether STAT5 could also regulate miR-16 expression in these cell lines. RNA 1 4 9
interference-mediated down-regulation of STAT5 indeed increased miR-16 level to the same is inhibited in MOLM-14 cells, and not at all when FLT3-ITD is inhibited or STAT5 is 1 8 0 down-regulated in MV4-11 cells ( Supplementary Fig 2 A The STAT5/miR-16/CDC25A axis is specific to FLT3-ITD AML cells 1 8 8
We then examined whether these molecular pathways specifically work downstream of 1 8 9 FLT3-ITD. In order to do this, we first used the HEL leukemic cell line, which expresses the 1 9 0 mutant tyrosine kinase JAK2V617F but not the FLT3 receptor, and in which we previously 1 9 1 described a STAT5-dependent regulation of CDC25A (11). As shown in figure 4A, RNA 1 9 2
interference-mediated down-regulation of STAT5 actually induced a dramatic decrease in 1 9 3 CDC25A protein level, but inhibiting miR-16, which was modestly increased under these 1 9 4 conditions (figure 4B), did not restore CDC25A protein level. This indicates that STAT5 1 9 5 regulation of CDC25A does not depend on miR-16 in this cell line. In the OCI-AML3 1 9 6 leukemic cell line, which expresses wild type FLT3, activating FLT3 with FLT3 ligand, or 1 9 7
inhibiting the receptor with AC220, modified neither CDC25A protein nor the miR-16 level 1 9 8
( Figure 4C -D). Overall, these data obtained in human leukemic cells suggest that several 1 9 9 different signaling pathways operate in different cell lines to regulate CDC25A, and that the 2 0 0 STAT5/miR-16/CDC25A pathway specifically acts downstream of the FLT3-ITD mutant 2 0 1 receptor in AML.
2 0 2 2 0 3
MiR-16 regulates FLT3-ITD AML cell proliferation and differentiation 2 0 4
Considering that we identified CDC25A as a master regulator of FLT3-ITD AML 2 0 5 proliferation and differentiation, we decided to investigate whether this is also the case for effects of FLT3 inhibitors. We then tested the importance of miR-16 in a MOLM-14-TKD 2 1 2 cell line that is resistant to FLT3-ITD inhibition (7, 18) . Overexpressing miR-16 also reduced 2 1 3 cell proliferation in this case, suggesting that targeting this pathway could overcome some of 2 1 4 the resistance observed with FLT3-ITD kinase inhibitors ( Figure 5A ). In accordance with 2 1 5 these results, the clonogenic potential of primary cells from a FLT3-ITD-positive patient was 2 1 6 reduced when miR-16 was overexpressed, while there was no impact in FLT3wt primary 2 1 7 samples ( Figure 5C ).
1 8
In addition to proliferation, we then examined whether miR-16 down-regulation by FLT3-2 1 9
ITD was involved in the differentiation block of these cells. As seen in figure 5D , miR-16 2 2 0 expression induced differentiation of MOLM-14 cells, as indicated by increased expression of 2 2 1 the cell surface differentiation marker CD11b. Interestingly, this was also the case in MOLM-2 2 2
14-TKD cells that are resistant to FLT3 inhibition, but not in cells that express wild type 2 2 3 FLT3 (OCI-AML3). Finally, we also observed re-expression of the CD14 but not the CD15 1 0 surface differentiation marker with miR-16 overexpression (figures 5E and F), suggesting that 2 2 5 monocytic rather than granulocytic differentiation was induced by miR-16 in FLT3-ITD cells, 2 2 6
which is highly consistent with our previous work on CDC25A (7). In this work we investigated the molecular mechanisms that control CDC25A transcription 2 3 0 and translation in acute myeloid leukemia cells that express the FLT3-ITD mutant tyrosine 2 3 1 kinase receptor. This investigation picks up where our previous study leaves off, in which we 2 3 2 identified this phosphatase as a master determinant of proliferation and differentiation arrest 2 3 3 in this leukemic subtype (7). In general, CDC25A expression is tightly regulated in myeloid 2 3 4 malignancies that express tyrosine kinase mutations (7, 11, 19) in which STAT5 and STAT3 2 3 5 pathways are most often activated. Transcriptional regulations of CDC25A by E2F1 (20), 2 3 6 myc (21) and STAT3 (22) have been described previously in different cellular contexts.
3 7
However, the question of STAT5-mediated transcriptional regulation of CDC25A remained 2
3 8 an open one. In our study, STAT5 is identified at the CDC25A promoter for the first time, and 2 3 9
we highlight the importance of STAT5 activity for proper CDC25A transcription downstream 2 4 0 of the FLT3-ITD receptor. It has been reported that STAT3 associates with myc or Rb to 2 4 1 respectively activate or inhibit CDC25A transcription (22). Therefore, whether STAT5 2 4 2 associates with transcriptional partners to finely tune CDC25A transcription in AML cells 2 4 3 remains an interesting question.
4 4
The importance of STAT factors in hematological models has been extensively documented 2 4 5 (23, 24), and researchers have been taking interest in the clinical relevance of these factors as 2 4 6 targets in various cancer models (25, 26) . Recently, a study in MDS and AML models showed 2 4 7
an impairment in leukemic growth in vivo and an increase in differentiation in primary 2 4 8 progenitor cells with the use of a clinical antisense nucleotide that targets STAT3 (27). Our
2
In a previous work, Kim et al described a down-regulation of miR-16 by FLT3-ITD (17).
7 5
Pim1 regulation by miR-16 has been described in a murine cell line model overexpressing 2 7 6 FLT3-ITD (17). However our data do not support the argument that Pim1 is a miR-16 target 2 7 7
in the human FLT3-ITD AML cell lines MOLM-14 and MV4-11 (see figure 3E ). It remains 2 7 8
to be established whether this discrepancy is due to the distinct AML cell models used in both 2 7 9 studies or to other unknown parameters. However, considering that transcriptional regulation of myeloid differentiation, has been described as a miR-16 target (39). Whether or not the 2 9 5 miR-16-dependent differentiation that we observed in FLT3-ITD AML cells is linked with 2 9 6 these pathways remains to be investigated. With regards to its cancer relevance, another 2 9 7
interesting miR-16 target that has been established is the anti-apoptotic protein Bcl2 (40).
9 8
Bcl2 inhibitors are currently being introduced as potential therapeutic tools in AML (41), and 1 3 interestingly, a synergy between venetoclax and the FLT3-inihibitor quizartinib has been 3 0 0 described (42). It would be interesting to establish whether miR-16-dependent regulation of 3 0 1
Bcl2 is involved in this process. 3 0 8
All cells were cultured at 37°C and 5% CO 2 in a humidified incubator, and were regularly 3 0 9
tested for mycoplasma contamination. To generate lentiviral vectors that express the micro-RNA 16, the miR-16 hairpin sequence 3 9 1 was cloned into the pLKO.1 lentiviral vector. We used 293T packaging cells co-transfected 3 9 2 with lentiviral protein (GAG, POL, and REV) that encode plasmids and our control (a 3 9 3 scrambled shRNA hairpin sequence) or miR-16 plasmids. Supernatants containing lentivirus 3 9 4
were collected for the next two day. Patient cells were thawed, plated at 1.5 million cells/ml 1 7 
3 8
Actin was used as a loading control in the western blot experiments. 
MOLM14 MV411
A.
B. Trypan blue cell count (10 6 cells/mL) A.
Figure 1

MV411 MOLM14
MOLM14 TKD
OCI-AML3
premiR Ctrl premiR-16 (72h) C. 
WT #11 WT #3 ITD #12
Ctrl miR16(72h)
WT #11 WT #3
ITD #12 
OCI-AML3
MOLM14
MOLM14 TKD MV411 MOLM14
